Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 28, 2012; 18(36): 5065-5071
Published online Sep 28, 2012. doi: 10.3748/wjg.v18.i36.5065
Table 1 Disease activity index evaluation according to Mayo score
Stool frequencyMucosal appearanceRectal bleedingPhysician’s overall assessment of disease severity
0Normal number of stools for the patientNormalNoneNormal
11-2 stools/d more than normalMild friabilityStreaks of bloodMild
23-4 stools/d more than normalModerate friabilityObvious bloodModerate
35 or more stools/d more than normalExudation, spontaneous bleedingMostly bloodSevere
Table 2 Features of patients enrolled into the study
Patients featuresAllUCCD
No. of patients14104
Sex (F/M)5/95/50/4
Age (yr), mean ± SD49.4 ± 17.754.9 ± 17.534.7 ± 7.6
Disease duration at enrollment (yr), mean ± SD4.8 ± 3.14.9 ± 3.14.5 ± 3.7
Diagnosis
Pancolitis8--
Distal colitis2--
Colonic CD4--
DAI at time of enrollment, median ± SE7 ± 46.5 ± 57 ± 2
DAI after the treatment, median ± SE2 ± 22 ± 21.5 ± 2
HI at time of enrollment, median ± SE1 ± 11 ± 11.5 ± 1
HI after the treatment, median ± SE0.5 ± 10.5 ± 10.5 ± 1
DAI at time of enrollment, mean ± SD6.6 ± 2.46.6 ± 2.76.5 ± 1.7
DAI after treatment, mean ± SD1.9 ± 1.52.0 ± 1.61.5 ± 1.3
HI at time of enrollment, mean ± SD1.4 ± 0.51.4 ± 0.51.5 ± 0.6
HI after treatment, mean ± SD0.5 ± 0.50.5 ± 0.50.5 ± 0.6
Time between 1st and 2nd colonoscopy (wk), mean ± SD4.7 ± 45.1 ± 4.63 ± 2.8
Other therapy (n)
Mesalazine651
AZA312
Deflazacort110
No other therapy431